Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

Trial Details

NCT ID
NCT05433142
Phase
PHASE1
Sponsor
Xencor, Inc.
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • XmAb819
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Duarte, California, United States|34.13945,-117.97729
  • Sacramento, California, United States|38.58157,-121.4944
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by the local site investigator. Lesi…
  • Subjects who have relapsed and refractory ccRCC, pRCC, NSCLC, and CRC with evidence of disease progression on standard-of-care therapies
  • ECOG performance status of 0 or 1.
  • All subjects must have adequate tumor sample available (slides or archival FFPE blocks)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →